Dermata Therapeutics Total Risk Alpha
| DRMAW Stock | | | USD 0.02 -0.0018 -9.84% |
Historical market data for Dermata Therapeutics Warrant forms the basis of the Total Risk Alpha indicator shown here. The calculation draws on time-series market data across available periods. Coverage may vary depending on data availability and normalization methods. Dermata Therapeutics has ROE of -2.03%. Review
Investing Opportunities for broader portfolio context. The portfolio view reflects current allocation structure. The allocation view reflects recorded position information. A position in Dermata Therapeutics Warrant is part of the allocation. This appears in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
For information on how to trade Dermata Stock refer to our
How to Trade Dermata Stock guide.
Dermata Therapeutics Warrant has current Total Risk Alpha of 2.12. The total risk alpha measures the performance of an asset by comparing its returns with those of a selected benchmark portfolio.
Total Risk Alpha | = | RFR + (ER[b] - ER[a]) | x | STD[a] / STD[b] |
| = | 2.12 | |
| ER[a] | = | Expected return on investing in Dermata Therapeutics |
| ER[b] | = | Expected return on market index or selected benchmark |
| STD[a] | = | Standard Deviation of returns on Dermata Therapeutics |
| STD[b] | = | Standard Deviation of selected market or benchmark |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
Total Risk Alpha Peers Comparison
Total Risk Alpha Relative To Other Indicators
Dermata Therapeutics Warrant is rated
below average for total risk alpha across the peer group. It is currently under evaluation for maximum drawdown across the peer group reflecting a
34.23 ratio of Maximum Drawdown to Total Risk Alpha. Dermata Therapeutics Warrant's Maximum Drawdown exceeds Total Risk Alpha by a factor of
34.23 The benchmark portfolio represents the market risk matched to the total risk of the stock ETF or fund.
Compare Dermata Therapeutics to Peers
Other Technical Indicators